Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF STRATEGY OFFICER | April 07, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 23,130 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 2,726 · Balance 23,976 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-04-07 · Tax withholding · Disposed 846 · Balance 23,130 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 2,726 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 8, 2026 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001867899-26-000004 · form4-04082026_080406.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 846 | $48.94 | $41,403.24 |
DisclosureSEC source: 0001867899-26-000004 · form4-04082026_080406.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,130 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001867899-26-000004 · form4-04082026_080406.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · derivative · entry 9 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,371 Underlying: Class A Ordinary Share · 2,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · derivative · entry 8 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,490 Underlying: Class A Ordinary Share · 1,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · derivative · entry 7 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,772 Underlying: Class A Ordinary Share · 1,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 16,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,600 Underlying: Class A Ordinary Share · 16,600 shares Expires not disclosed F5 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F6 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. F6 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 8,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 Underlying: Class A Ordinary Share · 8,300 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,200 | $0.00 Strike: $48.13 | $0.00 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · derivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,200 Underlying: Class A Ordinary Share · 33,200 shares Expires 2036-03-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,756 | $48.13 | $84,516.28 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,250 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 5,975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| January 15, 2026 Filed Apr 3, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 365 | $24.16 | $8,818.40 |
DisclosureSEC source: 0001867899-26-000002 · form4-04032026_080412.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,031 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2025 to January 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001867899-25-000013 · form4-12172025_091235.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 6,000 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 12,048 | $41.56 | $500,714.88 |
DisclosureSEC source: 0001867899-25-000013 · form4-12172025_091235.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,666 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.235 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,000 | $8.83 | $52,980.00 |
DisclosureSEC source: 0001867899-25-000013 · form4-12172025_091235.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 200 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001867899-25-000011 · form4-12012025_091206.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,938 Underlying: Class A Ordinary Share · 200 shares Expires 2031-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 200 | $42.89 | $8,578.00 |
DisclosureSEC source: 0001867899-25-000011 · form4-12012025_091206.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,714 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 200 | $22.89 | $4,578.00 |
DisclosureSEC source: 0001867899-25-000011 · form4-12012025_091206.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,500 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001867899-25-000009 · form4-11192025_091118.xml · derivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Class A Ordinary Share · 6,500 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 11,825 | $41.30 | $488,372.50 |
DisclosureSEC source: 0001867899-25-000009 · form4-11192025_091118.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,714 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.61 and $41.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 645 | $40.08 | $25,851.60 |
DisclosureSEC source: 0001867899-25-000009 · form4-11192025_091118.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,539 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.61 and $40.585. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,500 | $8.83 | $57,395.00 |
DisclosureSEC source: 0001867899-25-000009 · form4-11192025_091118.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,500 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001867899-25-000007 · form4-10162025_041001.xml · derivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Ordinary Share · 6,500 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 553 | $37.99 | $21,008.47 |
DisclosureSEC source: 0001867899-25-000007 · form4-10162025_041001.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,684 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.98 and $38.00. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 11,815 | $37.65 | $444,834.75 |
DisclosureSEC source: 0001867899-25-000007 · form4-10162025_041001.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,237 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.98 and $37.97. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,500 | $8.83 | $57,395.00 |
DisclosureSEC source: 0001867899-25-000007 · form4-10162025_041001.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 42,000 | $0.00 Strike: $17.92 | $0.00 |
DisclosureSEC source: 0001867899-25-000005 · form4-10012025_081048.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 42,000 shares Expires 2029-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 42,000 | $38.33 | $1,609,860.00 |
DisclosureSEC source: 0001867899-25-000005 · form4-10012025_081048.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,552 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.92 and $38.85. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 42,000 | $17.92 | $752,640.00 |
DisclosureSEC source: 0001867899-25-000005 · form4-10012025_081048.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,500 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001867899-25-000003 · form4-09172025_080944.xml · derivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,000 Underlying: Class A Ordinary Share · 6,500 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 356 | $37.00 | $13,172.00 |
DisclosureSEC source: 0001867899-25-000003 · form4-09172025_080944.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,552 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.865 and $37.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 16,044 | $36.45 | $584,803.80 |
DisclosureSEC source: 0001867899-25-000003 · form4-09172025_080944.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,908 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.83 and $36.74. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,500 | $8.83 | $57,395.00 |
DisclosureSEC source: 0001867899-25-000003 · form4-09172025_080944.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 13,389 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · derivative · entry 8 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 13,389 shares Expires 2030-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 13,389 | $35.66 | $477,451.74 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · nonDerivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,452 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.52 and $35.84. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 13,389 | $15.52 | $207,797.28 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · nonDerivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 46,546 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · derivative · entry 7 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,389 Underlying: Class A Ordinary Share · 46,546 shares Expires 2030-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 38,725 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,249 Underlying: Class A Ordinary Share · 38,725 shares Expires 2030-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 85,271 | $35.52 | $3,028,825.92 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,452 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.50 and $35.545. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 46,546 | $15.52 | $722,393.92 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 38,725 | $15.50 | $600,237.50 |
DisclosureSEC source: 0001415889-25-023878 · form4-09082025_080944.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 15,026 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · derivative · entry 17 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,974 Underlying: Class A Ordinary Share · 15,026 shares Expires 2030-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 65 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · derivative · entry 16 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,935 Underlying: Class A Ordinary Share · 65 shares Expires 2030-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 15,091 | $35.50 | $535,730.50 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · nonDerivative · entry 9 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,452 F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.50 and $35.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 15,026 | $15.50 | $232,903.00 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · nonDerivative · entry 8 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 65 | $15.52 | $1,008.80 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · nonDerivative · entry 7 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · derivative · entry 15 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 1,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 950 | $34.28 | $32,566.00 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · nonDerivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,452 Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · nonDerivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023587 · form4-09032025_090925.xml · derivative · entry 14 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,726 Underlying: Class A Ordinary Share · 2,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.